{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:05:31Z","timestamp":1789553131354,"version":"build-2803163510"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ctrv.2020.102109","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T21:50:15Z","timestamp":1601329815000},"page":"102109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Association of immune checkpoint inhibitors with respiratory infections: A review"],"prefix":"10.1016","volume":"90","author":[{"given":"Ryosuke","family":"Hamashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0651-7767","authenticated-orcid":false,"given":"Junji","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshie","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Iwasaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadaaki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2020.102109_b0005","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0058-2019","article-title":"Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer","volume":"28","author":"Cadranel","year":"2019","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.ctrv.2020.102109_b0010","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3109\/10428199309148203","article-title":"Potential sites of infection that develop in febrile neutropenic patients","volume":"10","author":"Nov\u00e1kov\u00e1","year":"1993","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2020.102109_b0015","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and Its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.ctrv.2020.102109_b0020","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102109_b0025","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102109_b0030","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1046\/j.1365-2567.2000.00121.x","article-title":"CD28, CTLA-4 and their ligands: Who does what and to whom?","volume":"101","author":"Sansom","year":"2000","journal-title":"Immunology"},{"key":"10.1016\/j.ctrv.2020.102109_b0035","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: A moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102109_b0040","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102109_b0045","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2016.72.1985","article-title":"Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: The checkmate 016 study","volume":"35","author":"Hammers","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102109_b0050","doi-asserted-by":"crossref","unstructured":"Svabek C, Chang K, Svabek C, Vazquez-guillamet C, Sato B, Rasche D, et al. Targeting the programmed cell death 1\u00a0: Programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis Targeting the programmed cell death 1\u00a0: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with se 2016:1\u201315. https:\/\/doi.org\/10.1186\/cc13176.","DOI":"10.1186\/cc13176"},{"key":"10.1016\/j.ctrv.2020.102109_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/cc9354","article-title":"PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction","volume":"14","author":"Zhang","year":"2010","journal-title":"Crit Care"},{"key":"10.1016\/j.ctrv.2020.102109_b0060","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/cid\/ciw539","article-title":"The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma","volume":"63","author":"Del Castillo","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ctrv.2020.102109_b0065","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ctrv.2020.102109_b0070","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cmi.2017.12.003","article-title":"Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment","volume":"24","author":"Picchi","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ctrv.2020.102109_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aat2702","article-title":"Tuberculosis following PD-1 blockade for cancer immunotherapy","volume":"11","author":"Barber","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ctrv.2020.102109_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2020.00487","article-title":"The role of PD-1 in acute and chronic infection","volume":"11","author":"Jubel","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2020.102109_b0085","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2020.102109_b0090","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2020.102109_b0095","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.rmed.2018.11.021","article-title":"Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy","volume":"146","author":"Fujita","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.ctrv.2020.102109_b0100","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2019.00207","article-title":"The PD-1\/PD-L1 axis and virus infections: A delicate balance","volume":"9","author":"Sch\u00f6nrich","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.ctrv.2020.102109_b0105","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1128\/JVI.02892-15","article-title":"Immunodominant dengue virus-specific CD8 + T cell responses are associated with a memory PD-1 + phenotype","volume":"90","author":"de Alwis","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.ctrv.2020.102109_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0059599","article-title":"Lack of PD-L1 expression by iNKT cells improves the course of influenza A infection","volume":"8","author":"Maazi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2020.102109_b0115","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1128\/JVI.02851-13","article-title":"Highly pathological influenza A virus infection is associated with augmented expression of PD-1 by functionally compromised virus-specific CD8+ T Cells","volume":"88","author":"Rutigliano","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.ctrv.2020.102109_b0120","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.2217\/imt-2018-0080","article-title":"INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A transversal challenge. the INVIDIa study","volume":"10","author":"Bersanelli","year":"2018","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ctrv.2020.102109_b0125","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/cid\/ciz202","article-title":"Safety of inactivated influenza vaccine in cancer patients receiving immune checkpoint inhibitors","volume":"70","author":"Chong","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ctrv.2020.102109_b0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0353-7","article-title":"Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events","volume":"6","author":"L\u00e4ubli","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2020.102109_b0135","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejca.2018.09.012","article-title":"Influenza vaccination in patients with lung cancer receiving anti\u2013programmed death receptor 1 immunotherapy does not induce immune-related adverse events","volume":"104","author":"Wijn","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2020.102109_b0140","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.chom.2020.05.008","article-title":"Type I and Type III interferons \u2013 induction, signaling, evasion, and application to combat COVID-19","volume":"27","author":"Park","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ctrv.2020.102109_b0145","doi-asserted-by":"crossref","first-page":"6303","DOI":"10.1073\/pnas.0809422106","article-title":"PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis","volume":"106","author":"Huang","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ctrv.2020.102109_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2020.00827","article-title":"Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)","volume":"11","author":"Diao","year":"2020","journal-title":"Front Immunol"},{"issue":"05","key":"10.1016\/j.ctrv.2020.102109_b0155","article-title":"Determinants of severity in cancer patients with COVID-19 illness","volume":"2020","author":"Robilotti","year":"2020","journal-title":"MedRxiv"},{"key":"10.1016\/j.ctrv.2020.102109_b0160","first-page":"CD-20-0596","article-title":"Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers","author":"Luo","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2020.102109_b0165","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1172\/JCI62860","article-title":"Viral acute lower respiratory infections impair CD8 + T cells through PD-1","volume":"122","author":"Erickson","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2020.102109_b0170","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/mi.2014.106","article-title":"Control of pathogenic effector T-cell activities in situ by PD-L1 expression on respiratory inflammatory dendritic cells during respiratory syncytial virus infection","volume":"8","author":"Yao","year":"2015","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.ctrv.2020.102109_b0175","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2249.2004.02338.x","article-title":"CTLA-4 blockade inhibits induction of Helicobacter pylori-associated gastritis in mice","volume":"135","author":"Watanabe","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ctrv.2020.102109_b0180","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.4049\/jimmunol.1000743","article-title":"B7\u2013H1 (programmed cell death ligand 1) is required for the development of multifunctional Th1 cells and immunity to primary, but not secondary, Salmonella infection","volume":"185","author":"Lee","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2020.102109_b0185","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1182\/blood-2009-02-203141","article-title":"PD-1 on dendritic cells impedes innate immunity against bacterial infection","volume":"113","author":"Yao","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102109_b0190","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.4049\/jimmunol.1401673","article-title":"PD-1 suppresses protective immunity to streptococcus pneumoniae through a B cell-intrinsic mechanism","volume":"194","author":"McKay","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2020.102109_b0195","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/CJI.0b013e31823aa41c","article-title":"Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma","volume":"35","author":"Weber","year":"2012","journal-title":"J Immunother"},{"key":"10.1016\/j.ctrv.2020.102109_b0200","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1001\/jama.2011.1829","article-title":"Immunosuppression in patients who die of sepsis and multiple organ failure","volume":"306","author":"Boomer","year":"2011","journal-title":"JAMA - J Am Med Assoc"},{"key":"10.1016\/j.ctrv.2020.102109_b0205","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1007\/s00134-019-05704-z","article-title":"Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab","volume":"45","author":"Hotchkiss","year":"2019","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ctrv.2020.102109_b0210","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/imr.12274","article-title":"T cells and adaptive immunity to Mycobacterium tuberculosis in humans","volume":"264","author":"Jasenosky","year":"2015","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ctrv.2020.102109_b0215","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/infdis\/jit206","article-title":"Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon \u03b3-producing T cells from apoptosis in patients with pulmonary tuberculosis","volume":"208","author":"Singh","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ctrv.2020.102109_b0220","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.3389\/fimmu.2018.01995","article-title":"PD-1 expression on mycobacterium tuberculosis-specific CD4 T cells is associated with bacterial load in human tuberculosis","volume":"9","author":"Day","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2020.102109_b0225","doi-asserted-by":"crossref","first-page":"13402","DOI":"10.1073\/pnas.1007394107","article-title":"Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis","volume":"107","author":"L\u00e1z\u00e1r-Moln\u00e1r","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ctrv.2020.102109_b0230","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.4049\/jimmunol.1003304","article-title":"CD4 T cells promote rather than control tuberculosis in the absence of PD-1\u2013mediated inhibition","volume":"186","author":"Barber","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2020.102109_b0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.ppat.1005667","article-title":"CD4 T Cell-derived IFN-\u03b3 plays a minimal role in control of pulmonary mycobacterium tuberculosis infection and must be actively repressed by PD-1 to prevent lethal disease","volume":"12","author":"Sakai","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ctrv.2020.102109_b0240","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/S1470-2045(19)30674-6","article-title":"Immune checkpoint inhibitors and tuberculosis: an old disease in a new context","volume":"21","author":"Langan","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102109_b0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofaa126","article-title":"Incidence of active tuberculosis in lung cancer patients receiving immune checkpoint inhibitors","volume":"7","author":"Fujita","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ctrv.2020.102109_b0250","doi-asserted-by":"crossref","unstructured":"Jennifer Fishovitz\u00a7, Juan A. Hermoso#, Mayland Chang\u00a7 and SM \u00a7Department. \u57fa\u56e0\u7684\u6539\u53d8NIH Public Access. Bone 2008;23:1\u20137. https:\/\/doi.org\/10.1038\/jid.2014.371.","DOI":"10.1038\/jid.2014.371"},{"key":"10.1016\/j.ctrv.2020.102109_b0255","doi-asserted-by":"crossref","first-page":"105853","DOI":"10.1016\/j.rmed.2019.105853","article-title":"Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors","volume":"161","author":"Im","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.ctrv.2020.102109_b0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep42004","article-title":"Attenuation of lymphocyte immune responses during Mycobacterium avium complex-induced lung disease due to increasing expression of programmed death-1 on lymphocytes","volume":"7","author":"Shu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2020.102109_b0265","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.2169\/internalmedicine.1195-18","article-title":"Improvement of mycobacterium abscessus pulmonary disease after nivolumab administration in a patient with advanced non-small cell lung cancer","volume":"57","author":"Ishii","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.ctrv.2020.102109_b0270","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/ofid\/ofaa067","article-title":"Development of mycobacterium avium complex lung disease in patients with lung cancer on immune checkpoint inhibitors","volume":"7","author":"Fujita","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ctrv.2020.102109_b0275","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1073\/pnas.0711918105","article-title":"The PD-1\/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungus Histoplasma capsulatum","volume":"105","author":"L\u00e1z\u00e1r-Moln\u00e1r","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ctrv.2020.102109_b0280","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1128\/IAI.68.8.4624-4630.2000","article-title":"CTLA-4 down-regulates the protective anticryptococcal cell-mediated immune response","volume":"68","author":"McGaha","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.ctrv.2020.102109_b0285","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.4049\/jimmunol.1700840","article-title":"Anti\u2013PD-1 antibody treatment promotes clearance of persistent cryptococcal lung infection in mice","volume":"199","author":"Roussey","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2020.102109_b0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hiv.12676","article-title":"Shedding light on IRIS: from pathophysiology to treatment of cryptococcal meningitis and immune reconstitution inflammatory syndrome in HIV-infected individuals","volume":"20","author":"Balasko","year":"2019","journal-title":"HIV Med"},{"key":"10.1016\/j.ctrv.2020.102109_b0295","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2010-05-285080","article-title":"Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome","volume":"116","author":"Antonelli","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102109_b0300","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1093\/infdis\/jiu664","article-title":"Cellular immune activation in cerebrospinal fluid from ugandans with cryptococcal meningitis and immune reconstitution inflammatory syndrome","volume":"211","author":"Meya","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ctrv.2020.102109_b0305","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1165\/rcmb.2019-0234OC","article-title":"PD-1 deficiency promotes macrophage activation and T-helper Cell Type 1\/T-helper cell type 17 response in pneumocystis pneumonia","volume":"62","author":"Zhang","year":"2020","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.ctrv.2020.102109_b0310","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/infdis\/jix469","article-title":"Aspergillus fumigatus cell wall a-(1,3)-glucan stimulates regulatory T-cell polarization by inducing PD-L1 expression on human dendritic cells","volume":"216","author":"Stephen-Victor","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ctrv.2020.102109_b0315","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/rcr2.289","article-title":"Acute progression of aspergillosis in a patient with lung cancer receiving nivolumab","volume":"6","author":"Uchida","year":"2018","journal-title":"Respirol Case Reports"},{"key":"10.1016\/j.ctrv.2020.102109_b0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/rcr2.580","article-title":"Destroyed lung due to sustained inflammation after chemoradiotherapy followed by durvalumab","volume":"8","author":"Taima","year":"2020","journal-title":"Respirol Case Reports"},{"key":"10.1016\/j.ctrv.2020.102109_b0325","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S1473-3099(16)30541-2","article-title":"Nivolumab plus interferon-\u03b3 in the treatment of intractable mucormycosis","volume":"17","author":"Grimaldi","year":"2017","journal-title":"Lancet Infect Dis"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722030147X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722030147X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:24:47Z","timestamp":1759656287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573722030147X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":65,"alternative-id":["S030573722030147X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102109","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of immune checkpoint inhibitors with respiratory infections: A review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102109","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102109"}}